In contrast, one study of melanoma patients who developed hypophysitis while on treatment with ipilimumab (anti-CTLA-4) showed that those who received lower dose corticosteroids had substantially better survival compared to those treated with high-dose corticosteroids [40]. Here, CTLA4 is linked to melanoma.